my "trading strategy" for ip is buy and hold until brilacidin becomes a mainstream drug with many applications.
It is well on its way.
It is disappointing B OM results were good but not great. It slows down our march forward, without allowing for a big surge of momentum: let's face it- no other secondary data release -yet- is NOT GOOD for long shareholders and does not help make the IP case for B OM